562 related articles for article (PubMed ID: 10744594)
21. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?
Vis AN; van der Sluis TM; Al-Itejawi HHM; van Moorselaar RJA; Meuleman EJH
Urol Oncol; 2015 Jan; 33(1):7-15. PubMed ID: 25159013
[TBL] [Abstract][Full Text] [Related]
22. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
23. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
24. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
25. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
[TBL] [Abstract][Full Text] [Related]
26. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
Walker LM; Tran S; Robinson JW
Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
[TBL] [Abstract][Full Text] [Related]
27. Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review.
Zhang X; Zhang G; Wang J; Wang Y
Front Endocrinol (Lausanne); 2023; 14():1131715. PubMed ID: 36814583
[TBL] [Abstract][Full Text] [Related]
28. Maximal androgen blockade for advanced prostate cancer.
Schmitt B; Bennett C; Seidenfeld J; Samson D; Wilt T
Cochrane Database Syst Rev; 2000; 1999(2):CD001526. PubMed ID: 10796804
[TBL] [Abstract][Full Text] [Related]
29. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
30. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
31. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
[TBL] [Abstract][Full Text] [Related]
32. Is the flare phenomenon clinically significant?
Bubley GJ
Urology; 2001 Aug; 58(2 Suppl 1):5-9. PubMed ID: 11502435
[TBL] [Abstract][Full Text] [Related]
33. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
34. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
[TBL] [Abstract][Full Text] [Related]
35. [Hormonal therapy for prostatic cancer--state of the art].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):305-8. PubMed ID: 15714983
[TBL] [Abstract][Full Text] [Related]
36. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
37. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in hormonal therapy for advanced prostate cancer.
Oottamasathien S; Crawford ED
Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
[TBL] [Abstract][Full Text] [Related]
39. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
40. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Chodak GW
Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]